prostate cancer that had spread to other parts of their body but who still responded to androgen-deprivation therapy.
“We’re slowly starting to see a migration of drugs traditionally saved for advanced stages of the disease, where we’re incorporating them into earlier stages of the disease,” said Dr. Bobby Liaw, medical director of the Blavatnik Family Chelsea Medical Center at Mount Sinai, in New York City. He was not involved in the trials.
Apalutamide combined with androgen-deprivation therapy caused a 33% reduction in the overall risk of death, compared against patients who received a placebo alongside their androgen-deprivation therapy, said the lead researcher of that clinical trial, Dr. Kim Chi.
Apalutamide also delayed the progression of cancer by 52%, and the length of time before patients required chemotherapy by 61%, said Chi, medical director of the Clinical Trials Unit at the BC Cancer Agency-Vancouver Prostate Center in Canada.
Adding the hormone blocker significantly improved patients’ outcomes with